ASH Annual Meeting and Exposition | Conference

Dual BCMA/CD19 CAR T-cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

December 8th 2025

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

December 8th 2025

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis

December 7th 2025

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL

December 7th 2025

Treating with targeted therapy for the first 4 cycles showed potential curative intent without impacting patient response to subsequent chemotherapy.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Blinatumomab Plus Ponatinib Shows Survival Advantage Over Chemo/TKI Regimen in Ph+ ALL

December 7th 2025

Initial results from the phase 3 GIMEMA ALL2830 trial support the use of this chemotherapy-free approach as a new SOC for adult Ph-positive ALL.

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

December 7th 2025

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM

December 7th 2025

The “all-antibody–based” doublet generated high VGPR or better rates and had a favorable safety profile in the front line for this patient population.

Zanubrutinib Demonstrates Long-Term Efficacy, Safety in Relapsed/Refractory CLL/SLL

December 7th 2025

Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.

Pirtobrutinib Matches Ibrutinib in ORR, Shows Potential PFS Edge in BTK Inhibitor–Naive CLL/SLL

December 7th 2025

Pirtobrutinib yeilds superior overall response rates and promising progression-free survival compared to ibrutinib in chronic lymphocytic leukemia.

Epcoritamab Plus Rituximab and Lenalidomide Improves PFS in Pretreated Follicular Lymphoma

December 7th 2025

The addition of epcoritamab to lenalidomide and rituximab improved PFS and ORR vs the combination alone in relapsed/refractory follicular lymphoma.

Gintemetostat Shows Early Activity and Manageable Safety in Triple-Class Refractory Multiple Myeloma

December 7th 2025

Gintemetostat demonstrates efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Epcoritamab Plus R-mini-CHOP May Aid in Treatment of Elderly Patients with First-Line DLBCL

December 7th 2025

Epcoritamab plus R-mini-CHOP delivered deep responses with manageable safety in elderly, high-risk patients with newly diagnosed DLBCL.

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

December 7th 2025

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Real-World Data Suggest ctDNA Status More Accurately Captures EFS Outcomes Than PET-CT

December 6th 2025

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Axatilimab Dosing Shift Shows Feasibility in cGVHD

December 6th 2025

The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.

Odronextamab Plus CHOP Produces Deep, Potentially Durable Responses in Previously Untreated DLBCL

December 6th 2025

Early phase 3 data showed signals of efficacy with the addition of odronextamab to CHOP in patients with previously untreated DLBCL and high-risk features.